As I and others have speculated all along, the 6 cohort design could lead to some or all of the 3 T315i cohorts being ended early for that specific indication. We're talking months for them to prove improvements over no treatment (as none exists).
I did step away for a few minutes and volume shot up 10 fold...looking for 7.50+ today, holding the gains.
News 
Market Data 
Discover 
